BMRN vs JEF · P/E 40, rev $2.85B vs P/E 18, rev $10.52B
Biomarin Pharmaceutical Inc (BMRN) versus Jefferies Financial Group Inc (JEF) — a side-by-side from cached financials, not a winner call.
Biomarin Pharmaceutical Inc (BMRN) is a biotechnology company listed on NASDAQ.
Jefferies Financial Group Inc (JEF) is a capital markets company listed on US.
Latest reported BMRN revenue for 2024-12-31 was $2.85B. Net income was $426.9M. Revenue was up 18.0% from 2023-12-31 to 2024-12-31. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
Latest reported JEF revenue for 2024-11-30 was $10.52B. Net income was $716.0M. Revenue was up 41.3% from 2023-11-30 to 2024-11-30. JEF currently screens at market cap $10.77B and trailing P/E 17.7.
BMRN currently screens at market cap $10.63B and trailing P/E 39.6. JEF currently screens at market cap $10.77B and trailing P/E 17.7.
Not investment advice. Open the BMRN and JEF stock pages for the full models.
Not investment advice.